Members of the UT Southwestern team whose research successfully halted progression of a form of muscular dystrophy in mice included (l-r) Dr. Chengzu Long, Dr. Eric Olson, Dr. Rhonda Bassel-Duby, Dr. Leonela Amoasii, John Shelton, and Alex Mireault.
If efficiently and safely scaled up in DMD patients, this technique could lead to one of the first successful genome editing-based treatments for this fatal disease, researchers said.
DMD, the most common and severe form of muscular dystrophy among boys, is characterized by progressive muscle degeneration and weakness. It is caused by mutations in the X-linked DMD gene that encodes the protein dystrophin. The disease affects one in 3,500 to 5,000 boys, according to the Centers for Disease Control and Prevention and other estimates, and often leads to premature death by the early 30s.
Although the genetic cause of DMD has been known for nearly 30 years, no effective treatments exist. The disease breaks down muscle fibers and replaces them with fibrous or fatty tissue, causing the muscle to gradually weaken. This condition often results in heart muscle disease, or cardiomyopathy, the leading cause of death in these patients.
In the study published today in Science, UTSW researchers used a gene-editing approach to permanently correct the DMD mutation that causes the disease in young mice.
“This is different from other therapeutic approaches, because it eliminates the cause of the disease,” said senior author Dr. Eric Olson, Chairman of Molecular Biology, and Co-Director of the Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center at UT Southwestern.
In 2014, Dr. Olson’s team first used this technique – called CRISPR/Cas9-mediated genome editing – to correct the mutation in the germ line of mice and prevent muscular dystrophy. This paved the way for novel genome editing-based therapeutics in DMD. It also raised several challenges for clinical applications of gene editing. Since germ line editing is not feasible in humans, strategies would need to be developed to deliver gene-editing components to postnatal tissues.
To test this out, researchers delivered gene-editing components to the mice via adeno-associated virus 9 (AAV9). DMD mice treated with this technique produced dystrophin protein and progressively showed improved structure and function of skeletal muscle and heart.
“AAV9 can efficiently infect humans in a tissue-specific manner, but it does not cause human disease or toxicity. It’s a molecular missile for gene therapy,” said Dr. Leonela Amoasii, a postdoctoral researcher in the Olson lab and co-lead author of the study with Dr. Chengzu Long, Instructor of Molecular Biology.
“The CRISPR/Cas9 system is an adaptive immune system of single-celled organisms against invading virus. Ironically, this system was hijacked, we packaged it into a nonpathogenic virus, and corrected a genetic mutation in an animal model,” added Dr. Long.
The CRISPR genome-editing technology, which was developed by a researcher at University of California at Berkeley, was picked as the “Breakthrough of the Year” scientific development by Science.
“This study represents a very important translational application of genome editing of DMD mutations in young mice. It’s a solid step toward a practical cure for DMD,” said Dr. Rhonda Bassel-Duby, Professor of Molecular Biology and Co-Principal Investigator of a genomic editing project with Dr. Olson at the Wellstone Center.
“Importantly, in principle, the same strategy can be applied to numerous types of mutations within the human DMD patients,” added Dr. Olson, who also serves as Director of the Hamon Center for Regenerative Science and Medicine, and holds the Annie and Willie Nelson Professorship in Stem Cell Research, the Pogue Distinguished Chair in Research on Cardiac Birth Defects, and the Robert A. Welch Distinguished Chair in Science.
Now, the research team is working to apply this gene-editing technique to cells from DMD patients and in larger preclinical animal models.
Read more: Gene-editing technique successfully stops progression of Duchenne muscular dystrophy
The Latest on: Duchenne muscular dystrophy
via Google News
The Latest on: Duchenne muscular dystrophy
- Parent Project Muscular Dystrophy Announces Pediatric Certified Duchenne Care Center, Billings Clinicon August 4, 2022 at 7:45 am
Parent Project Muscular Dystrophy (PPMD), a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne), announced the expansion of their renowned Certified Duchenne Care ...
- Entrada Therapeutics Announces Collaboration with the Myotonic Dystrophyon August 4, 2022 at 5:35 am
The natural history study will generate data to further the ongoing efforts of the myotonic dystrophy research community to understand disease progression and identify potential clinical outcome ...
- Edgewise Therapeutics Reports Second Quarter 2022 Financial Resultson August 4, 2022 at 5:00 am
Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treatment of rare muscle disorders, ...
- Sarepta's Duchenne Gene Therapy Update Gets Bullish Stance From Analystson August 3, 2022 at 11:20 am
Sarepta Therapeutics Inc (NASDAQ: SRPT) reported above-consensus 2Q FY22 product sales of $211 million and provided more details on the path forward for SRP-9001 gene therapy for Duchenne muscular ...
- Oxford-Harrington Rare Disease Centre to Advance Novel Treatment for Duchenne Muscular Dystrophyon August 2, 2022 at 7:16 am
New therapy seeks to protect from rare muscle-wasting disorder OXFORD, England and CLEVELAND, Aug. 2, 2022 /PRNewswire/ -- The Oxford-Harrington ...
- More drama ahead: Sarepta plans to file for accelerated Duchenne approval, with adcomm a 'near certainty'on July 29, 2022 at 8:53 am
While Sarepta has three antisense oligonucleotide therapies approved — albeit not without controversy — for Duchenne muscular dystrophy, it has been working on a long-term treatment in the form of a ...
- Sarepta to ask FDA for accelerated approval of Duchenne gene therapyon July 29, 2022 at 8:46 am
After discussions with the FDA, the biotech aims to submit an application this fall — sooner than expected and ahead of a Phase 3 study that’s now ongoing.
- Sarepta looks for quick approval for Duchenne muscular dystrophy gene therapy treatmenton July 29, 2022 at 7:13 am
Sarepta is looking for accelerated approval for SRP-9001 to treat ambulant individuals with Duchenne muscular dystrophy.
- Sarepta to seek early FDA approval for gene therapy to treat Duchenne muscular dystrophyon July 29, 2022 at 6:23 am
Sarepta Therapeutics said that it intends to file an earlier-than-expected application to U.S. regulators, seeking approval for a gene therapy to treat Duchenne muscular dystrophy.
- Global Duchenne Muscular Dystrophy Drugs Market Size, Share Remuneration to Surge At 28.9% CAGR Through 2026on July 11, 2022 at 3:36 am
Jul 11, 2022 (Market Insight Reports) -- The report Duchenne Muscular Dystrophy Drugs Market Size and Analysis maintains enhanced dynamics and is overshadowed by a top player across the globe.
via Bing News